Source:http://linkedlifedata.com/resource/pubmed/id/18209026
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2008-1-22
|
pubmed:abstractText |
The recombinant human (rh) myelin/oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) model in the common marmoset is characterized by 100% disease incidence, a chronic disease course, and a variable time interval between immunization and neurological impairment. We investigated whether monkeys with fast and slow disease progression display different anti-MOG T or B cell responses and analyzed the underlying pathogenic mechanism(s). The results show that fast progressor monkeys display a significantly wider specificity diversification of anti-MOG T cells at necropsy than slow progressors, especially against MOG(34-56) and MOG(74-96). MOG(34-56) emerged as a critical encephalitogenic peptide, inducing severe neurological disease and multiple lesions with inflammation, demyelination, and axonal injury in the CNS. Although EAE was not observed in MOG(74-96)-immunized monkeys, weak T cell responses against MOG(34-56) and low grade CNS pathology were detected. When these cases received a booster immunization with MOG(34-56) in IFA, full-blown EAE developed. MOG(34-56)-reactive T cells expressed CD3, CD4, or CD8 and CD56, but not CD16. Moreover, MOG(34-56)-specific T cell lines displayed specific cytotoxic activity against peptide-pulsed B cell lines. The phenotype and cytotoxic activity suggest that these cells are NK-CTL. These results support the concept that cytotoxic cells may play a role in the pathogenesis of multiple sclerosis.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Autoantibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Myelin Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Myelin-Associated Glycoprotein,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/myelin oligodendrocyte glycoprotein,
http://linkedlifedata.com/resource/pubmed/chemical/myelin oligodendrocyte...
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0022-1767
|
pubmed:author |
pubmed-author:'t HartBert ABA,
pubmed-author:BauerJanJ,
pubmed-author:BlezerErwinE,
pubmed-author:BrokHerbert P MHP,
pubmed-author:HintzenRogier QRQ,
pubmed-author:JagessarS AnwarSA,
pubmed-author:KapYolanda SYS,
pubmed-author:LamanJon DJD,
pubmed-author:RemarqueEdE,
pubmed-author:SmithPaulP,
pubmed-author:StrijkersGustav JGJ
|
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
180
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1326-37
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:18209026-Animals,
pubmed-meshheading:18209026-Autoantibodies,
pubmed-meshheading:18209026-Autoimmunity,
pubmed-meshheading:18209026-Brain,
pubmed-meshheading:18209026-Callithrix,
pubmed-meshheading:18209026-Disease Progression,
pubmed-meshheading:18209026-Encephalomyelitis, Autoimmune, Experimental,
pubmed-meshheading:18209026-Female,
pubmed-meshheading:18209026-Glycoproteins,
pubmed-meshheading:18209026-Humans,
pubmed-meshheading:18209026-Lymphocyte Activation,
pubmed-meshheading:18209026-Male,
pubmed-meshheading:18209026-Myelin Proteins,
pubmed-meshheading:18209026-Myelin-Associated Glycoprotein,
pubmed-meshheading:18209026-Peptide Fragments,
pubmed-meshheading:18209026-Recombinant Proteins,
pubmed-meshheading:18209026-T-Lymphocytes, Cytotoxic
|
pubmed:year |
2008
|
pubmed:articleTitle |
Fast progression of recombinant human myelin/oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis in marmosets is associated with the activation of MOG34-56-specific cytotoxic T cells.
|
pubmed:affiliation |
Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, The Netherlands.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|